- Home
- MSD vs TIL Comparison
MSD vs TIL Comparison
Compare MSD & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSD
- TIL
- Stock Information
- Founded
- MSD 1993
- TIL 2018
- Country
- MSD United States
- TIL United States
- Employees
- MSD N/A
- TIL N/A
- Industry
- MSD Trusts Except Educational Religious and Charitable
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- MSD Finance
- TIL Health Care
- Exchange
- MSD Nasdaq
- TIL Nasdaq
- Market Cap
- MSD 154.7M
- TIL 177.1M
- IPO Year
- MSD N/A
- TIL 2021
- Fundamental
- Price
- MSD $7.27
- TIL $15.05
- Analyst Decision
- MSD
- TIL Strong Buy
- Analyst Count
- MSD 0
- TIL 5
- Target Price
- MSD N/A
- TIL $100.67
- AVG Volume (30 Days)
- MSD 70.2K
- TIL 75.3K
- Earning Date
- MSD 01-01-0001
- TIL 11-13-2025
- Dividend Yield
- MSD 11.26%
- TIL N/A
- EPS Growth
- MSD N/A
- TIL N/A
- EPS
- MSD N/A
- TIL N/A
- Revenue
- MSD N/A
- TIL N/A
- Revenue This Year
- MSD N/A
- TIL N/A
- Revenue Next Year
- MSD N/A
- TIL N/A
- P/E Ratio
- MSD N/A
- TIL N/A
- Revenue Growth
- MSD N/A
- TIL N/A
- 52 Week Low
- MSD $6.11
- TIL $10.80
- 52 Week High
- MSD $7.46
- TIL $42.79
- Technical
- Relative Strength Index (RSI)
- MSD 37.60
- TIL 34.49
- Support Level
- MSD $7.26
- TIL $18.10
- Resistance Level
- MSD $7.46
- TIL $20.11
- Average True Range (ATR)
- MSD 0.08
- TIL 1.16
- MACD
- MSD -0.01
- TIL -0.31
- Stochastic Oscillator
- MSD 4.00
- TIL 3.54
About MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.